NaV1.6 also presents an interesting therapeutic target for CBD, CBGA, and CBDVA, because inhibition of NaV1.6 reduces epileptiform events in a zebrafish model of DS, providing a neuronal counterbalance to the haploinsufficiency of the Scn1a model (Weuring et al., 2020). This evidence concerns the gene SCN1A and Dravet syndrome.